Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle.

Plain-language guide to PMID 12705363 (2003): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 adults.

Key Facts

PMID: 12705363
Journal: Journal of pediatric endocrinology & metabolism : JPEM
Year: 2003
Study type: Randomized Controlled Trial
Authors: Dörr HG et al. (13 authors)
DOI: 10.1515/jpem.2003.16.3.383

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

In an open-label, randomized, 4-period crossover study, 18 healthy adults received single subcutaneous injections of Genotropin administered by the Genotropin ZipTip needle-free device and by conventional injection.

Bioequivalence was established between the devices.

Who Took Part

The study group was 18 adults.

PubMed indexes the participants as young children, children, teenagers and adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label, crossover and multicenter study.

The adults were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Nothing was hidden in this open-label Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study: the adults and staff both knew the treatment.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

More than one site took part, so the adults came from several places.

What Was Measured

Topics PubMed links to this paper include Contusions, Hemorrhage, Human Growth Hormone, Injections, Jet, Patient Acceptance of Health Care and Therapeutic Equivalency.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2003 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.